Brief: Mithra, Lotus Announce Approval Of Alyssa In Taiwan, Hong Kong

Mithra Pharmaceuticals SA

21/09/2022 06:37

Sept 21 (Reuters) - MITHRA PHARMACEUTICALS SA  MITRA.BR :
    * MITHRA AND LOTUS ANNOUNCE APPROVAL OF ALYSSA®, AN
INNOVATIVE
ORAL CONTRACEPTIVE, IN BOTH TAIWAN AND HONG KONG
    * LOTUS ANTICIPATES COMMERCIAL LAUNCH OF ALYSSA®
CONTRACEPTIVE
PILL BY Q1 2023 IN TAIWAN, FOLLOWED BY HONG KONG LATER IN YEAR
    * UNDER PARTNERSHIP WITH MITHRA, LOTUS WILL BE EXCLUSIVELY
MARKETING ALYSSA® IN BOTH TAIWAN AND HONG KONG TO PURSUE OVERALL
CONTRACEPTIVE MARKET WORTH US$25 MILLION, GROWING AT A 3-YEAR
CAGR OF 11% SINCE 2019
    * ALYSSA®, DEVELOPED BY MITHRA, IS FIRST AND ONLY ORAL
CONTRACEPTIVE DRUG CONTAINING ESTETRO
    * UPON LAUNCH, ALYSSA® WILL COMPETE IN THE TAIWANESE ORAL
CONTRACEPTIVE MARKET WHICH WAS VALUED AT US$14MILLION IN 2021
AND CURRENTLY MAINLY DOMINATED IN TAIWAN BY ETHINYL
ESTRADIOLBASED ESTROGEN SOLUTIONS
    * LOTUS WILL ALSO MARKET THE PRODUCT IN HONG KONG TO CAPTURE
THE
MARKET POTENTIAL OF APPROXIMATELY US$11 MILLION AS OF 2021

Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))